Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)
Clinical trial NCT03703050 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03703050
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-02
- Primary completion
- 2026-04-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.